# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Mitchell Kapoor reiterates Halozyme Therapeutics (NASDAQ:HALO) with a Buy and maintains $65 ...
HC Wainwright & Co. analyst Mitchell Kapoor reiterates Halozyme Therapeutics (NASDAQ:HALO) with a Buy and maintains $65 ...
Benchmark analyst Robert Wasserman maintains Halozyme Therapeutics (NASDAQ:HALO) with a Buy and raises the price target from...
Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") today announced that Roche received European Commission (EC) mar...
HC Wainwright & Co. analyst Mitchell Kapoor reiterates Halozyme Therapeutics (NASDAQ:HALO) with a Buy and maintains $65 ...
Mid-cap stocks saw significant gains last week, with top performers like AGIO, VRNT, and NVAX, causing analysts to raise their ...